Suppr超能文献

志贺毒素引起的溶血尿毒症综合征危重症患者的临床特征。

Clinical features of critically ill patients with Shiga toxin-induced hemolytic uremic syndrome.

机构信息

Department of Intensive Care, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

出版信息

Crit Care Med. 2013 Jul;41(7):1702-10. doi: 10.1097/CCM.0b013e31828a24a8.

Abstract

OBJECTIVE

In Spring 2011, an unprecedented outbreak of Shiga toxin-producing Escherichia coli serotype O104:H4-associated hemolytic uremic syndrome occurred in Northern Germany. The aim of this study was to describe the clinical characteristics, treatments, and outcomes of critically ill patients with Shiga toxin-producing E. coli-associated hemolytic uremic syndrome during this outbreak.

DESIGN, SETTING, AND PATIENTS: Multicenter, retrospective, observational study of critically ill adult patients with Shiga toxin-producing E. coli-associated hemolytic uremic syndrome in six hospitals in Hamburg, Germany, between May 2011 and August 2011.

MEASUREMENTS AND MAIN RESULTS

During the study period, 106 patients with Shiga toxin-producing E. coli-associated hemolytic uremic syndrome were admitted to eight ICUs. The median age was 40 years (range, 18-83) with a female:male ratio of 3:1. The median time from onset of clinical symptoms to hospital admission was 3 days and from hospital to ICU admission an additional 3 days. A total of 101 patients (95.3%) had acute renal failure and 78 (73.6%) required renal replacement therapy. Intubation and mechanical ventilation were required in 38 patients (35.8%) and noninvasive ventilation was required in 17 patients (16.0%). The median duration of invasive ventilation was 7 days (range, 1-32 days) and the median ICU stay was 10 days (range, 1-45 days). Fifty-one patients (48.1%) developed sepsis; of these 51 patients, 27 (25.4%) developed septic shock. Seventy patients (66.0%) developed severe neurological symptoms. Ninety-seven patients (91.5%) were treated with plasma exchange and 50 patients (47.2%) received eculizumab (monoclonal anti-C5 antibody). The mortality rate was 4.7%. Mild residual neurological symptoms were present in 21.7% of patients at ICU discharge, and no patient required renal replacement therapy 6 months after ICU admission.

CONCLUSIONS

During the 2011 Shiga toxin-producing E. coli-associated hemolytic uremic syndrome outbreak in Germany, critical illness developed rapidly after hospital admission, often in young women. The infection was associated with severe neurological and renal symptoms, requiring mechanical ventilation and renal replacement therapy in a substantial proportion of patients. Overall, recovery was much better than expected.

摘要

目的

2011 年春,德国北部暴发了史无前例的产志贺毒素大肠埃希菌 O104:H4 相关溶血性尿毒综合征。本研究旨在描述暴发期间重症产志贺毒素大肠埃希菌相关溶血性尿毒综合征患者的临床特征、治疗方法和结局。

设计、地点和患者:2011 年 5 月至 8 月,德国汉堡六家医院的重症成人产志贺毒素大肠埃希菌相关溶血性尿毒综合征患者进行了多中心、回顾性、观察性研究。

测量和主要结果

研究期间,8 家 ICU 共收治 106 例产志贺毒素大肠埃希菌相关溶血性尿毒综合征患者。中位年龄为 40 岁(范围 18-83 岁),女性与男性比例为 3:1。从临床症状发作到住院的中位时间为 3 天,从住院到入住 ICU 的中位时间为 3 天。101 例(95.3%)患者存在急性肾衰竭,78 例(73.6%)需要肾脏替代治疗。38 例(35.8%)患者需要气管插管和机械通气,17 例(16.0%)患者需要无创通气。有创通气的中位时间为 7 天(范围 1-32 天),ICU 住院的中位时间为 10 天(范围 1-45 天)。51 例(48.1%)患者发生脓毒症,其中 27 例(25.4%)发生感染性休克。70 例(66.0%)患者出现严重神经系统症状。97 例(91.5%)患者接受血浆置换治疗,50 例(47.2%)患者接受依库珠单抗(单克隆抗 C5 抗体)治疗。死亡率为 4.7%。ICU 出院时,21.7%的患者有轻度残留神经系统症状,无患者在 ICU 入院后 6 个月需要肾脏替代治疗。

结论

在德国 2011 年产志贺毒素大肠埃希菌相关溶血性尿毒综合征暴发期间,入院后迅速发展为重症,常发生于年轻女性。该感染与严重的神经和肾脏症状相关,需要相当一部分患者进行机械通气和肾脏替代治疗。总体而言,恢复情况好于预期。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验